Endocyte Cancer Drugs Clinical Pipeline Insight

Publish Date:- Nov-2016       No Of Pages (32)

Electronic Access - Single User License $500 Buy Now
CD-ROM Mail Delivery $800Buy Now
Hard Copy Mail Delivery $800 Buy Now
Electronic Access - Multi-User License $1000 Buy Now


“Endocyte - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Endocyte. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “8” cancer drugs in clinical pipeline.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Endocyte - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.


“Endocyte - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Endocyte. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “8” cancer drugs in clinical pipeline.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Endocyte - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.

1. Endocyte

  1.1 Business Overview

  1.2 Endocyte Cancer Pipeline Overview

 

2. Enocyte Cancer Drugs in Research Phase

  2.1 Small Molecule Ligand-Fluorescent Dye Conjugates - OnTarget Laboratories

 

3. Endocyte Cancer Drugs in Preclinical Phase

  3.1 Cancer Therapeutics – Endocyte

 

4. Endocyte Cancer Drugs in Phase-I

  4.1 EC 1169

  4.2 EC 1456

  4.3 EC 0652

 

5. Endocyte Cancer Drugs in Phase-II

  5.1 Folate Fluorescein Isothiocyanate Conjugate

  5.2 Technetium Tc99m Etarfolatide

  5.3 Vintafolide

 

6. No Development Reported in Cancer Drugs in Clinical Pipeline

  6.1 EC 0489

  6.2 EC 0225

 

7. Preregistration Submission Withdrawal in Cancer Drugs in Clinical Pipeline

  7.1 Folic Acid Intravenous – Endocyte

  7.2 FolateImmune Therapy - Endocyte/Purdue University

 

8. Suspended in Cancer Drugs in Clinical Pipeline

  8.1 BMS 753493


Figure 1-1: Endocyte Cancer Pipeline by Phase (%)

Figure 1-2: Endocyte Cancer Pipeline by Phase (Number)

Figure 1-3: Endocyte Cancer Drugs No Development Reported & Suspended in Clinical Pipeline by Phase (%)

Figure 1-4: Endocyte Cancer Drugs No Development Reported & Suspended in Clinical Pipeline by Phase (Number)